TED Ted Baker Plc

RNS Number:8123Y
Tepnel Life Sciences PLC
23 February 2006





              Tepnel Life Sciences plc ('Tepnel' or 'the Company')

              UPDATE ON DEVELOPMENT OF CONTRACT ANALYSIS FACILITY



Manchester UK, 23 February, 2006: Tepnel Life Sciences PLC has completed the
purchase of 1.7 acres of land in Livingston, Scotland for the construction of a
dedicated pharmaceutical, protein and genomic analysis facility.  The 18,000
square foot state-of-the-art laboratory will allow Tepnel to consolidate its
existing pharmaceutical services business into a single location with its
primary function being the analysis of therapeutic proteins including
recombinant and affinity purified proteins for use as therapeutic agents and
vaccines.  The Company will also expand it pharmacogenomics capabilities to
include high throughput genotyping and other genomic analysis techniques.



Ben Matzilevich, Tepnel's CEO, says "this is an important milestone in our
long-term strategy to provide the most competitive platform for our existing
pharmaceutical analysis services. It will also allow us to continue the
successful development of some of our most specialized products and services in
high growth areas such as pharmacogenomics and new generations of vaccines.



I especially would like to thank Scottish Enterprise Edinburgh and Lothian for
its continued support of this project, without which we could not have
proceeded, and also the support of the Scottish Executive through their
provision of an RSA grant which is helping Tepnel create value within the
Scottish economy through the creation of jobs as a result of this project.  This
facility, which will be owned by Tepnel, will enable our Research Products &
Services group to use our mass spectrometry capabilities in building our
position in the rapidly evolving therapeutic protein market.  Additionally, we
shall expand our capabilities in bio-and immunoassays of these therapeutic
molecules for our pharmaceutical and biotechnology customers.



By building and owning a facility such as this we will have created a valuable
asset for Tepnel which will give the Company significant flexibility for further
expansion and growth.  Our objectives remain continued strong top line growth
and increasing bottom line profitability while maintaining a healthy pipeline of
new products and services directed to key market segments."







About Tepnel Life Sciences plc



Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two main divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 175 employees.  TLS provides test
kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research.  The company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets.  TLS focuses on these niche opportunities with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments.



More information on Tepnel can be found at www.tepnel.com.



Enquiries:

Carol Smith

Tepnel Life Sciences plc

Heron House, Oaks Business Park

Crewe Road, Wythenshawe

Manchester M23 9HZ

Tel: 0161 946 2220

Fax: 0161 946 2223

csmith@tepnel.co.uk



Richard Anderson

De Facto Communications Ltd

330 High Holborn

London WC1V 7QD

Tel: 020 7861 3838

Fax: 020 7861 3839

r.anderson@defacto.com

www.defacto.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCPUUCAPUPQGMP

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024